Royalty Pharma Beats Q1 Earnings and Revenue Estimates
Royalty Pharma (NASDAQ: RPRX) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $1.60 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 2.08%. A quarter ago, it was expected that this company would post earnings of $1.03 per share when it actually produced earnings of $1.15, delivering a surprise of 11.65%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Royalty Pharma, which belongs to the Zacks Financial – Miscellaneous Services industry, posted revenues of $717 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 6.79%. This compares to year-ago revenues of $1.13 billion. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock’s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management’s commentary on the earnings call.
Royalty Pharma …
Full story available on Benzinga.com